Working together to develop a screening platform to enhance the detection and management of Alzheimer’s disease.
PREDICTOM is an international across sector initiative to bring dementia diagnostics closer to the public through a customisable cognitive and biomarker screening platform.
Latest news
News
📄 At Home Alzheimer’s Detection Takes a Leap Forward
Imagine checking your brain health the way you check your blood pressure or sleep patterns—quickly, privately, and from the comfort of your own home. That vision is no longer futuristic speculation but the driving force behind PREDICTOM, a major European study that is quietly reshaping how Alzheimer’s disease might be detected long before symptoms appear.
News
🩺 Closing the Gap: Strengthening Europe’s Path to Timelier, Fairer Dementia Diagnosis
Have you ever wondered what happens when someone walks into their GP surgery worried about their memory - and whether that first step toward a dementia diagnosis looks the same across Europe?
News
PREDICTOM Level 2 Clinical Study has started
The PREDICTOM is pleased to announce the launch of Level 2 of its international clinical study—an important next step made possible entirely through the generosity, time, and commitment of participants across Europe. The participants' contributions continue to drive forward our shared goal: improving the early detection of Alzheimer’s disease through accessible, reliable, and science-driven tools.
PREDICTOM Study Progress
This page provides regularly updated information on the progress of the PREDICTOM study for everyone interested in following its development. The tracker will show progress for both Level 1 and Level 2 as the study advances.
Our mission
PREDICTOM will identify scalable biosignatures for early and accurate diagnosis of Alzheimer’s disease and personalized preventive interventions.